Healthcare Cybersecurity Companies: A Buyer's Selection Guide

Reviewed September 17, 2026

Buying security services for a hospital network is not the same purchase as buying security testing for a connected infusion pump headed toward an FDA submission. The term "healthcare cybersecurity companies" covers both, plus several categories in between, and vendors often blur the lines in their marketing. A hospital IT director needs different deliverables than a medical device engineering team preparing an eSTAR submission. Choosing the wrong category wastes budget and, for manufacturers, can produce documentation that a reviewer rejects outright. This guide breaks down the categories, the questions worth asking each one, and the specific evidence an FDA submission needs that many vendors cannot actually supply.

Why This Matters

Choosing a security vendor is a compliance decision as much as a technical one, especially for device manufacturers. The FDA's February 3, 2026 final guidance, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, expects specific documentation: threat models, architecture views, a software bill of materials, vulnerability testing results, and evidence that findings were assessed against a risk management file built to ISO 14971. A vendor that only performs generic vulnerability scanning, without mapping results to these expectations, leaves the manufacturer to do that translation work alone, often after the engagement has already ended.

Hospitals and health systems face a different but related problem. Their vendors need to demonstrate HIPAA safeguards, incident response readiness, and network segmentation, none of which map directly to a premarket submission. Buyers who conflate the two markets often discover the gap only when a reviewer sends a deficiency letter asking for evidence the vendor never intended to produce. Understanding the categories up front avoids that outcome and sets clearer expectations for cost, timeline, and deliverables before a contract is signed.

What Are the Categories of Healthcare Cybersecurity Companies?

Healthcare cybersecurity companies generally fall into four categories, each built around a different buyer and a different deliverable. Understanding which one you are actually talking to matters more than any brand name. The categories overlap in marketing language far more than they overlap in actual capability.

Hospital and health system managed security providers focus on network operations: firewalls, endpoint detection, security operations center monitoring, and incident response for the hospital's IT environment. They are built to protect a network perimeter and respond to intrusions across thousands of connected assets, including medical devices already deployed on the network. They are not typically equipped to test a device's firmware, evaluate its software architecture, or produce documentation aligned to a premarket submission.

Healthcare IT compliance and HIPAA specialists focus on administrative, physical, and technical safeguards required under HIPAA. They perform risk assessments, policy development, and audits aimed at covered entities and business associates. Their deliverables are compliance reports and policy documentation, useful for a hospital's regulatory posture but not aligned to the FDA's premarket cybersecurity content requirements, which follow a different framework entirely.

Medical device manufacturer-focused regulatory security testers specialize in the specific evidence a device maker needs: threat modeling, penetration testing scoped to device architecture, SBOM generation and vulnerability triage, and documentation formatted for eSTAR submission. This category is the smallest of the four and the one most manufacturers actually need when preparing a submission or responding to a postmarket obligation under Section 524B.

Product security tooling vendors sell software, not services: static and dynamic analysis tools, SBOM generation platforms, vulnerability management dashboards, and automated scanning. Tools are valuable inputs to a security program but do not, by themselves, produce the analysis, judgment, and documentation a reviewer expects to see behind the raw output.

[KEY REQUIREMENT] Before signing with any vendor, identify which category actually matches your problem. A tooling subscription will not produce a threat model, and a HIPAA compliance audit will not satisfy a premarket submission's testing evidence requirements.

What Should Each Category Actually Be Used For?

Each category is good for a specific problem, and buyers get the best results when they stop expecting one vendor to solve all four. Hospital managed security providers are the right choice for ongoing network defense, monitoring, and incident response across a live clinical environment. They are the correct answer when the question is "how do we detect and respond to an intrusion," not "how do we document device security for a submission."

HIPAA and compliance specialists are the right choice when the goal is meeting administrative and technical safeguard requirements, preparing for an Office for Civil Rights audit, or building organizational policy. They answer "are we compliant with HIPAA's Security Rule," which is a distinct question from device-level security testing.

Regulatory security testers focused on medical devices are the right choice when a manufacturer needs premarket submission evidence, postmarket vulnerability management support, or a threat model tied to a specific device's architecture and intended use. This is the category most relevant to engineering and regulatory affairs teams working toward an FDA submission deadline.

Product security tooling is the right choice as an input to any of the above, particularly for ongoing SBOM tracking and vulnerability monitoring, but it works best paired with people who can interpret the output and write it into a defensible narrative.

What Questions Should You Ask a Vendor Before Signing?

Ask a vendor to name the specific people who will perform the testing, not just the company credentials. Anonymous "our security team" language usually means the actual testers are subcontracted or junior staff without device-specific experience. Ask whether the deliverable will map findings to your device's intended use and risk management file, since a report that lists vulnerabilities without that mapping requires additional work before it is submission-ready.

Ask how the vendor handles SBOM generation and whether it aligns with the CISA 2026 SBOM Minimum Elements, which superseded the 2021 NTIA framework. Ask for a sample redacted report from a comparable device type, and read it closely for whether findings are tied to exploitability, patient impact, and mitigation status, or simply listed by CVE number and severity score.

See also: CVSS Scoring for Medical Devices: A Complete Walkthrough, Medical Device Software Development: A Compliance Guide, and When to Start Medical Device Cybersecurity.

[KEY REQUIREMENT] Ask directly whether the vendor has produced documentation that has gone through an actual FDA review cycle, and ask what changed after reviewer feedback. A vendor with real submission experience will have a specific answer, not a general claim of familiarity with the guidance.

What Evidence Does an FDA Submission Actually Need From a Vendor?

An FDA submission needs testing evidence that is traceable to a specific device, a specific version, and a specific risk management file entry, not a generic scan output. Under the February 3, 2026 final guidance, the eSTAR template's Cybersecurity attachment area expects a threat model, architecture and interface diagrams, an SBOM, vulnerability and penetration testing results, and a description of the postmarket vulnerability monitoring plan. Each of these needs to connect back to the device's ISO 14971 risk management file so a reviewer can see how a technical finding was translated into a documented risk decision.

A vendor's testing report should identify who performed the testing, what methodology was used, what was in and out of scope, and what the residual risk is for any unresolved finding. It should also state clearly whether a finding was mitigated, accepted, or transferred, language that maps directly to risk management terminology reviewers expect to see. A report that stops at a list of CVEs and CVSS scores leaves the hardest part of the work, the risk translation, for the manufacturer to do without vendor support.

What Are the Red Flags When Evaluating a Vendor?

A scan-report-only deliverable is the clearest red flag, since automated scanning output without manual analysis, exploitation context, or risk mapping does not meet the FDA's expectations for premarket testing evidence. A report that lists no named testers, only a company name and a generic methodology paragraph, suggests the vendor cannot stand behind specific findings if a reviewer asks follow-up questions.

No linkage to ISO 14971 is another warning sign. If a vendor cannot explain how a finding connects to your risk management file's severity and probability categories, the deliverable will need substantial rework before it supports a submission. Guaranteed clearance claims are a hard stop: no vendor can guarantee an FDA outcome, and any company that promises "guaranteed clearance" or "100% pass rate" is either overselling or does not understand how FDA review actually works.

[KEY REQUIREMENT] Treat "we've worked with the FDA before" as meaningless without specifics. Ask for the device type, the submission pathway, and what the reviewer's cybersecurity questions actually were.

How Blue Goat Cyber Approaches This

Blue Goat Cyber works specifically in the medical device manufacturer category, focused on the evidence a premarket or postmarket submission actually requires. Testing is performed by named engineers, findings are mapped to the device's intended use and risk management file, and reports are structured for the eSTAR Cybersecurity attachment area rather than delivered as a generic scan output. This includes medical device penetration testing scoped to device architecture, threat modeling tied to intended use, and SBOM services aligned to current minimum elements. Manufacturers evaluating vendors are welcome to ask the same questions raised in this guide and compare the answers directly against a specific submission need.

Frequently Asked Questions

Do I need a different vendor for HIPAA compliance and device security testing?

Usually yes. HIPAA compliance work addresses administrative, physical, and technical safeguards for covered entities and business associates, while device security testing addresses the technical architecture of a specific product headed toward an FDA submission. A vendor strong in one is rarely strong in both, and asking a HIPAA specialist for premarket testing evidence typically produces an incomplete deliverable.

Can a hospital's managed security provider help a medical device manufacturer with an FDA submission?

Generally no. Managed security providers are built around monitoring a hospital's network and responding to incidents across deployed assets, not testing a device's architecture or producing documentation aligned to premarket submission requirements. Manufacturers need a vendor whose deliverables are structured around device-level evidence and risk file traceability.

What is the difference between a vulnerability scan and the testing an FDA submission needs?

A vulnerability scan produces a list of known weaknesses matched against signatures or databases, largely automated and unfiltered by context. Submission-ready testing includes manual analysis, exploitability assessment specific to the device's use case, and a mapping of each finding to the risk management file, none of which an automated scan alone can produce.

How much does medical device security testing typically cost?

Cost depends heavily on device complexity, connectivity, and the scope of testing required, and any number quoted without knowing those specifics is unreliable. Ask vendors for a scoping call based on your device's architecture and intended use rather than relying on published price ranges.

Is it a red flag if a vendor cannot name the specific testers on my project?

Yes, this is one of the clearest warning signs. Named testers with device-specific experience should be identifiable in a proposal, and a vendor unwilling or unable to name who performs the work is harder to hold accountable for the quality of findings.

Should I choose a vendor based on the tools they use?

Tools matter less than the analysis behind them. A vendor with access to strong scanning tools but no process for translating findings into risk-file-linked evidence will still leave you with submission gaps, so evaluate the deliverable and the people, not the tool list.

CTA

If you are preparing a premarket submission or responding to a postmarket vulnerability and need testing evidence structured for FDA review, contact Blue Goat Cyber to scope the work against your device's architecture and submission timeline.